# Synthetic Lethality Master Documentation

**Last Updated:** January 28, 2025  
**Status:** âœ… V1 & V2 Complete | âœ… Sprint 1 Complete | â³ Publication Phase 1 In Progress (20%)

---

## Executive Summary

### Implementation Status
- **V1: Core Features** âœ… Complete - Production-ready frontend/backend
- **V2: AI & UI Enhancements** âœ… Complete - LLM explanations, animated UI
- **Sprint 1: SAE Biomarker Correlation** âœ… Complete - Statistical engine validated
- **Sprint 2: Feature Interpretation** ğŸ“‹ Planned
- **Publication: Benchmark & Model Improvement** â³ Phase 1 (20% complete)

### Current Performance
- **Frontend/Backend**: âœ… Production-ready, route `/synthetic-lethality`
- **Pilot Benchmark**: 50% drug match, 100% Evo2 usage (10 cases)
- **S/P/E Model**: 62.5% accuracy (needs improvement vs 75-87.5% rule-based baseline)
- **Target**: >80% accuracy to beat rule-based and demonstrate ML value

---

## Part 1: Implementation (Frontend/Backend)

### V1: Core Features (âœ… Complete)

**Components:**
- `SyntheticLethalityAnalyzer.jsx` - Main page
- `MutationInputForm.jsx` - Multi-gene input
- `EssentialityScoreCard.jsx` - Score display
- `PathwayDependencyDiagram.jsx` - Pathway visualization
- `TherapyRecommendationList.jsx` - Drug recommendations
- `ClinicalDossierModal.jsx` - Clinical dossier
- `useSyntheticLethality.js` - Analysis hook

**Route:** `/synthetic-lethality`

**API Endpoint:**
- **POST** `/api/guidance/synthetic_lethality`
- Returns: `suggested_therapy`, `essentiality_report`

### V2: Enhancements (âœ… Complete)

**AI-Powered Features:**
- Backend: `/api/llm/explain`, `/api/llm/chat`, `/api/llm/health`
- Frontend: `useLLMExplanation.js` hook, `AIExplanationPanel.jsx`
- Features: 3 audience types (clinician/patient/researcher), Q&A with context

**UI/UX Enhancements:**
- Score cards: Animated count-up, glassmorphism, hover effects, pulsing (â‰¥0.7)
- Pathway diagram: Clickable chips, animated connections, tooltips, popovers
- Dossier: AI summary generation, better PDF export

**Code Stats:**
- New files: 3 (1 backend, 2 frontend)
- Modified files: 4
- Lines added: ~800

### File Structure

**Frontend:**
```
oncology-coPilot/oncology-frontend/src/components/SyntheticLethality/
â”œâ”€â”€ SyntheticLethalityAnalyzer.jsx
â”œâ”€â”€ hooks/
â”‚   â”œâ”€â”€ useSyntheticLethality.js
â”‚   â””â”€â”€ useLLMExplanation.js (V2)
â””â”€â”€ components/
    â”œâ”€â”€ EssentialityScoreCard.jsx (V2 enhanced)
    â”œâ”€â”€ PathwayDependencyDiagram.jsx (V2 enhanced)
    â”œâ”€â”€ TherapyRecommendationList.jsx
    â”œâ”€â”€ MutationInputForm.jsx
    â”œâ”€â”€ ClinicalDossierModal.jsx (V2: AI summary)
    â””â”€â”€ AIExplanationPanel.jsx (V2)
```

**Backend:**
```
oncology-coPilot/oncology-backend-minimal/
â”œâ”€â”€ api/routers/
â”‚   â”œâ”€â”€ guidance.py
â”‚   â””â”€â”€ llm.py (V2)
â””â”€â”€ scripts/benchmark_sl/
    â”œâ”€â”€ benchmark_efficacy.py (âœ… false)
    â”œâ”€â”€ benchmark_synthetic_lethality.py (âš ï¸ Rules only)
    â””â”€â”€ download_depmap.py
```

### Critical Findings

1. **GUIDANCE_FAST Bypass:** `/api/guidance/synthetic_lethality` has fast-path that bypasses Evo2 for DDR genes â†’ returns hardcoded "platinum"
2. **Corrected Benchmark:** `benchmark_efficacy.py` uses `/api/efficacy/predict` â†’ tests real ML predictions
3. **Real Baseline:** 50% drug match is actual ML performance (not 85% from testing rules)

### Known Limitations

- API returns single `suggested_therapy` (not ranked list)
- Pathway detection must infer from `essentiality_report`
- Ground truth incomplete for many SL pairs
- Binary drug match only (no Top-3/Top-5)
- Sample size small (100 cases, aim for 500+)

---

## Part 2: SAE Biomarker Correlation (Sprint 1 & 2)

### Sprint 1: SAE Biomarker Correlation Engine (âœ… Complete)

**Objective:** Build statistical correlation engine to identify SAE features predictive of platinum response in TCGA-OV patients.

**Deliverables:**
- `BiomarkerCorrelationService` (379 lines) - 6 statistical methods
- Analysis execution script (163 lines) - 4 visualization plots
- RUO biomarker endpoint (`/api/sae/biomarker_summary`)

**Statistical Methods:**
- Pearson Correlation (continuous outcome encoding)
- Spearman Correlation (non-parametric robustness)
- Chi-Square Test (categorical analysis)
- Cohen's d Effect Sizes (sensitive vs refractory)
- Cross-Validation Stability (5-fold CV, â‰¥60% fold selection)
- Bootstrap Confidence Intervals (1000 iterations)
- Multiple Testing Correction (FDR - Benjamini-Hochberg)

**Thresholds:**
- P-value: < 0.01
- Effect size (Cohen's d): â‰¥ 0.3
- CV stability: â‰¥ 0.6
- Top N features: 100
- Random seed: 42 (reproducibility)

**Verification Results:**
- âœ… 100% synthetic signal detection (9/9 signals found)
- âœ… No false positives
- âœ… Perfect CV stability (1.0 for all signals)
- âœ… Massive effect sizes (Cohen's d: 8.5-21.8)
- âœ… Runtime: ~2 minutes (469 patients Ã— 32K features)

**Top Features Detected:**
- DDR features (100-102): Positive correlation (sensitive patients have higher values)
- MAPK features (200-202): Negative correlation (resistant/refractory patients have higher values)
- IO features (300-302): Moderate positive correlation

**Files Created:**
1. `api/services/biomarker_correlation_service.py` (379 lines)
2. `scripts/sae/analyze_biomarkers.py` (163 lines)
3. `api/resources/sae_feature_mapping_template.json` (template)
4. `data/validation/sae_cohort/sae_features_tcga_ov_platinum_MOCK.json` (865MB mock data)
5. `data/validation/sae_cohort/sae_tcga_ov_platinum_biomarkers_MOCK.json` (4.8KB results)

**Files Modified:**
1. `api/routers/sae.py` (added `/biomarker_summary` endpoint)

### Sprint 2: Feature Interpretation & Pathway Mapping (ğŸ“‹ Planned)

**Objective:** Transform raw SAE feature indices into interpretable biological mechanisms.

**Tasks:**
1. Featureâ†’Pathway mapping metadata (`api/resources/sae_feature_mapping.json`)
2. Extend SAE diagnostics with real mappings (`api/services/sae_feature_service.py`)
3. Mechanism-fit validation bridge (`scripts/sae/compare_sae_vs_proxy_mechanisms.py`)
4. Literature review for top features
5. Documentation & provenance

**Success Criteria:**
- Featureâ†’pathway mapping for top 20-50 features
- Diagnostics updated to use real mappings
- 3-5 pathways mapped (DDR, MAPK, IO, PI3K, TP53)
- Comparison script shows SAE aligns with proxy (correlation > 0.5)

---

## Part 3: Publication & Model Improvement

### Current Performance Analysis

**Baseline Comparison:**
- Random Baseline: 12.5-37.5% accuracy
- Rule-Based Baseline: 75.0-87.5% accuracy (CURRENT WINNER)
- S/P/E Model: 62.5% accuracy (NEEDS IMPROVEMENT)
- Target: >80% accuracy to beat rule-based and demonstrate ML value

**Problem Statement:**
- Rule-based uses simple DDR gene â†’ PARP mapping (works well on DDR-heavy dataset)
- S/P/E over-complicates simple patterns
- No explicit DDR â†’ PARP boost in drug scoring
- Limited test case coverage (8-10 cases vs 100 needed)

### Model Improvement Plan

#### Phase 0: Measurement Hygiene (Critical First Step)

**Non-negotiables** (aligned to S/P/E doctrine):
- Profiles must be explicit: Baseline (SP) vs Full (SPE) vs Fusion
- Flags must be explicit and logged:
  - `DISABLE_LITERATURE=1` (deterministic baseline)
  - `EVO_FORCE_MODEL=evo2_1b` (stable, cost-controlled)
  - `EVO_USE_DELTA_ONLY=1` (stable S-signal)
  - `DISABLE_FUSION=1` (unless GRCh38 coverage proven)
- Provenance mandatory: Every artifact includes `{run_id, profile, flags}`
- GRCh38 hygiene: No `ref:"?" alt:"?"` in coordinate-aware claims

**Evaluation Contract:**
- Report **Class@1** (correct drug class) and **Drug@1** (exact drug match) separately
- Include **Negative FP rate** (% negatives that get PARP recommendation)
- Use **identical denominators** across all methods
- Create **hard-set suite** (10-15 cases) where rule baseline should fail

**Hard-Set Suite Design:**
- TP53-only checkpoint cases (WEE1/ATR/CHK1 compete)
- ARID1A cases (ATR sensitivity patterns)
- "DDR present but likely benign" negatives (avoid false PARP)
- Non-DDR positives (force pathway/evidence reasoning)

#### Phase 1: Quick Wins (1-2 days)

**1.1: Add DDR â†’ PARP Explicit Rule**
- Boost PARP drugs when DDR genes present
- Behind feature flag `SL_PRIOR_BOOST=1` for A/B testing
- Expected: +10-15% accuracy (match rule-based baseline)

**1.2: Improve DDR Gene Detection**
- Expand DDR gene list (BRCA1/2, ATM, ATR, CHEK1/2, PALB2, RAD51C/D, MBD4, etc.)
- Gate by variant strength: LoF gets full boost, missense requires ClinVar pathogenic OR high Evo2 impact
- Expected: +5% accuracy, reduces false positives on benign DDR variants

**1.3: Adjust S/P/E Weights for SL Context**
- Increase Pathway weight when DDR detected (0.4 â†’ 0.5)
- Verify weights are actually tunable (not hardcoded)
- Expected: +5-10% accuracy

#### Phase 2: Medium-Term Improvements (1 week)

**2.1: Enhance Pathway Aggregation for DDR**
- Better gene â†’ pathway mapping
- Pathway disruption thresholds
- Multi-pathway interactions (BER + HRR)

**2.2: Improve Evidence Tier for PARP**
- BRCA1/2 â†’ PARP: Tier 1 (FDA approved)
- Other DDR â†’ PARP: Tier 2-3 (clinical trials)
- Evidence tier â†’ confidence boost

**2.3: Better Drug Ranking for SL Context**
- Split ranking: Stage 1 (class ranker) â†’ Stage 2 (within-class ranker)
- Context-aware: DDR â†’ prioritize PARP, HRD+ â†’ prioritize PARP

#### Phase 3: Advanced Optimizations (2 weeks)

**3.1: Machine Learning Calibration**
- Learn optimal S/P/E weights per cancer type
- Learn drug ranking preferences
- Learn pathway â†’ drug mappings

**3.2: Multi-Modal Integration**
- Combine S/P/E with synthetic lethality detection
- Use DepMap essentiality data (ovarian-lineage specific)
- Integrate essentiality scores as tie-breakers

**3.3: Expanded Test Case Validation**
- Run full 100-case benchmark
- Error analysis by gene/cancer type
- Targeted improvements

### Publication Execution Plan

**20 Deliverables Overview:**

**Phase 1: Zero-Cost Development (Days 1-3) - $0**
- D1: 100-case test dataset âœ…
- D2: Real DepMap data â³
- D3: Baseline comparison script âœ…
- D4: Ablation runner script âœ…
- D5: Mock response cache âœ…
- D6: Test case validator
- D7: Statistical analysis script
- D8: Error analysis framework

**Phase 2: Cache-Based Validation (Days 4-5) - $0**
- D9: Baseline comparison run (cached)
- D10: Ablation study run (cached)
- D11: Expanded benchmark results (cached)
- D12: Comparison table generator

**Phase 3: Strategic API Validation (Days 6-7) - ~$50**
- D13: Cache validation run (~$10)
- D14: Ablation validation (~$35)
- D15: Critical cases validation (~$3)
- D16: Error case analysis (~$2)

**Phase 4: Publication Assets (Days 8-10) - $0**
- D17: Figure 1 - System architecture
- D18: Figure 2 - Benchmark results
- D19: Figure 3 - Case study walkthrough
- D20: Figure 4 - Ablation results

**Progress:** 4/20 deliverables complete (20%)

### Code Reuse Strategy

**Existing Assets:**
- `benchmark_efficacy.py` - Benchmark runner (extend for ablation)
- `create_pilot_dataset.py` - Dataset creator (extend to 100 cases)
- `download_depmap.py` - DepMap processor (ready, needs CSV)
- `head_to_head_proxy_vs_true.py` - Bootstrap CI function (copy)
- `benchmark_efficacy.py::evaluate_prediction()` - Evaluation logic (reuse)
- `benchmark_efficacy.py::predict_efficacy()` - API client (reuse with cache wrapper)

**Cost-Efficient Testing:**
1. Mock cache (zero cost) - All Phase 1 & 2 development âœ…
2. Incremental validation (~$15) - Validate cache, test critical cases
3. Ablation testing (~$35) - 5 cases Ã— 7 modes for publication data
4. Full benchmark (~$100) - Only if needed for final validation

**Total Estimated Cost:** ~$50 (vs. $1000+ naive approach)

---

## Benchmark & Validation

### Pilot Results (âœ… Complete)

| Metric | Result | Target | Status |
|--------|--------|--------|--------|
| Drug Match Accuracy | 50% | >50% | âœ… Met |
| Evo2 Usage Rate | 100% | 100% | âœ… Perfect |
| Avg Confidence | 0.51 | - | âœ… Baseline |

**Case-by-Case:**
- âœ… BRCA cases correctly identified (5/5)
- âš ï¸ Negative controls got false positives (2/3)
- âŒ Some cases missed (3/10)

### Phased Approach

**Phase 1: 10 Cases (âœ… COMPLETE)**
- Goal: Validate infrastructure
- Result: 50% drug match, 100% Evo2 usage

**Phase 2: 50 Cases (ğŸ“‹ PENDING)**
- Goal: Reliable metrics
- Cost: ~50 Evo2 API calls

**Phase 3: 100 Cases (ğŸ“‹ PENDING)**
- Goal: Publication-ready
- Cost: ~100 Evo2 API calls

### Validation Metrics

| Metric | Target | Excellent |
|--------|--------|-----------|
| Drug Match | >70% | >85% |
| Essentiality Correlation | >0.7 | >0.85 |
| SL Detection TPR | >75% | >90% |
| SL Detection FPR | <20% | <10% |

### Ground Truth Sources

1. **DepMap Data** - CRISPR knockout scores (`Achilles_gene_effect.csv`)
2. **Known SL Pairs** - Literature (Lord & Ashworth 2017, DepMap)
3. **FDA Drug Labels** - DailyMed API
4. **TCGA Clinical Data** - Reuse existing ovarian dataset
5. **Negative Controls** - ClinVar benign + DepMap non-essential

### Benchmark Scripts

**âœ… CORRECT (Use This):**
- **File:** `scripts/benchmark_sl/benchmark_efficacy.py`
- **Endpoint:** `/api/efficacy/predict` (uses Evo2)
- **Usage:** `python benchmark_efficacy.py test_cases_pilot.json`

**âš ï¸ Original (Rules Only):**
- **File:** `scripts/benchmark_sl/benchmark_synthetic_lethality.py`
- **Issue:** GUIDANCE_FAST bypasses Evo2 for DDR genes

---

## Known SL Pairs (Literature with PMIDs)

| Gene | SL Partner | Drug | Evidence | PMID |
|------|-----------|------|----------|------|
| BRCA1 | PARP1 | Olaparib | FDA | 25366685 |
| BRCA2 | PARP1 | Niraparib | FDA | 28569902 |
| MBD4 | PARP1 | Olaparib | Preclinical | 30111527 |
| TP53 | ATR | Ceralasertib | Phase2 | 33115855 |
| TP53 | WEE1 | Adavosertib | Phase2 | 32592347 |
| ATM | PARP1 | Olaparib | Phase2 | 29880560 |
| PALB2 | PARP1 | Olaparib | Phase2 | 32592347 |
| RAD51C | PARP1 | Rucaparib | Phase2 | 30345854 |
| RAD51D | PARP1 | Rucaparib | Phase2 | 30345854 |
| ARID1A | ATR | Ceralasertib | Preclinical | 30510156 |
| CDK12 | PARP1 | Olaparib | Preclinical | 31320749 |

---

## Technical Details

### Current S/P/E Formula
```python
efficacy_score = 0.3 * seq_pct + 0.4 * path_pct + 0.3 * evidence + clinvar_prior
```

### Proposed Enhanced Formula
```python
# Base S/P/E score
base_score = 0.3 * seq_pct + 0.4 * path_pct + 0.3 * evidence + clinvar_prior

# DDR â†’ PARP boost (flagged)
if ddr_pathway_detected and drug in PARP_DRUGS:
    base_score += 0.2  # Explicit boost

# Context-aware weights
if ddr_pathway_score > 0.7:
    base_score = 0.25 * seq_pct + 0.5 * path_pct + 0.25 * evidence + clinvar_prior

final_score = min(1.0, base_score)  # Cap at 1.0
```

### DDR Gene Detection
```python
DDR_GENES = {
    "HRR": ["BRCA1", "BRCA2", "PALB2", "RAD51C", "RAD51D", "RAD51", "BRIP1", "RAD51B"],
    "BER": ["MBD4", "MUTYH", "OGG1", "NTHL1"],
    "NHEJ": ["ATM", "ATR", "CHEK1", "CHEK2", "TP53"],
    "FA": ["FANCA", "FANCD2", "FANCI", "FANCL"]
}
```

---

## Success Metrics

### Target Performance
- **Minimum**: Tie or exceed rule baseline on **Class@1**
- **Target**: Beat rule baseline on **hard-set** (where DDRâ†’PARP isn't enough)
- **Stretch**: Beat rule baseline on **Drug@1** while keeping negative-control FP rate low

### Publication-Ready Checklist
- [ ] 100+ validation cases with real ground truth
- [ ] >60% drug accuracy (vs ~17% random)
- [ ] Statistically significant superiority (p<0.05)
- [ ] Ablation studies proving S/P/E value
- [ ] 4+ publication-quality figures
- [ ] Complete manuscript draft
- [ ] Code availability statement

### Validation Strategy
1. **Hard-set first** (10-15 cases) - Prove lift where baseline fails
2. **Scale to 100** - Full benchmark suite
3. **Stratify results** - DDR-LoF, DDR-missense, non-DDR, negatives
4. **Re-enable evidence** - Measure optional lift after deterministic correctness locked

---

## Key Insights

### Insight 0: Measurement Hygiene Not Yet Achieved
- 62.5% vs 75.0% is directional, not publication-grade
- Comparison on 8-case pilot, not full 100
- Mixing two tasks: class selection vs within-class ranking
- Need proper evaluation contract first

### Insight 1: Rule Baseline Wins Due to Dataset Prior
- Dataset is DDRâ†’PARP heavy by design
- Simple heuristic matches dataset prior
- S/P/E only wins if it beats baseline on hard cases

### Insight 2: DDRâ†’PARP Boost Gets Parity, Not Lift
- Explicit boost closes gap but implements baseline inside model
- Publication value comes from:
  - Variant-level pathogenicity gating
  - Pair-aware special cases (BER+checkpoint)
  - Evidence-tier-aware confidence
  - Non-DDR SL mapping (ATR/WEE1/CHK1)

---

## Configuration

**Required for AI:**
```bash
GEMINI_API_KEY=your_key
# OR
OPENAI_API_KEY=your_key
```

**Optional:**
```bash
GUIDANCE_FAST=1  # Fast-path mode (default: enabled, bypasses Evo2 for DDR genes)
```

---

## Testing

### Manual Testing
1. Start services (backend + frontend)
2. Navigate to `/synthetic-lethality`
3. Load Ayesha's example (MBD4 + TP53)
4. Test AI explanations, pathway interactions, dossier export

### Benchmark Testing
```bash
cd scripts/benchmark_sl
python benchmark_efficacy.py test_cases_pilot.json
```

---

## Next Steps

### Immediate Actions
1. **D6**: Create test case validator (30 min)
2. **D7**: Create statistical analysis script (1 hour) - Copy bootstrap CI
3. **D8**: Create error analysis framework (1 hour) - Reuse evaluate_prediction
4. **D9-D12**: Run cache-based validations (2 hours)

**Estimated Time to Complete Phase 1**: 4-5 hours remaining

### Sprint 2 (When Ready)
- Create featureâ†’pathway mapping
- Update diagnostics with real mappings
- Build mechanism comparison script
- Conduct literature review
- Document findings

### Phase 2: Validation (ğŸ“‹ PENDING)
- Expand to 50 cases (~50 API calls)
- Ablation studies (S/P/E components)
- Compare to SOTA benchmarks

### Phase 3: Full Benchmark (ğŸ“‹ PENDING)
- 100 cases (~100 API calls)
- Comprehensive report
- Publication-ready results

---

## Cost Tracking

| Phase | API Calls | Cost | Status |
|-------|-----------|------|--------|
| Phase 1 | 0 | $0 | âœ… On track |
| Phase 2 | 0 | $0 | â³ Pending |
| Phase 3 | ~50 | ~$50 | â³ Pending |
| Phase 4 | 0 | $0 | â³ Pending |
| **TOTAL** | ~50 | ~$50 | âœ… Under budget |

**Total Estimated Cost**: ~$50 (vs. $1000+ naive approach)

---

**Status**: âœ… V1 & V2 Complete | âœ… Sprint 1 Complete | â³ Publication Phase 1 (20% Complete)  
**Single Source of Truth**: This document consolidates all Synthetic Lethality implementation, SAE biomarker correlation, and publication planning.












